Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer
Status:
Terminated
Trial end date:
2019-12-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if TAR-200, an investigational drug delivery
system, in combination with nivolumab is safe and tolerable in patients with muscle-invasive
bladder cancer (MIBC) who are scheduled for radical cystectomy (RC) during an 84-day dosing
cycle induction period comprised of four consecutive 21-day dosing cycles.